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Abstract
Purpose: To evaluate the effect of the anti-fibrotic protein serum amyloid P (SAP) on radiation-induced oral mucositis 
(OM) and fibrosis in a hamster cheek-pouch model.
Experimental Design: Hamsters received a single dose of radiation (40 Gy) to the left everted cheek pouch to induce 
significant OM. The protective therapeutic potential of SAP was evaluated using varying dosing regimens. The extent 
of OM was measured using a validated six-point scoring scheme ranging from 0 (normal tissue, no mucositis) to 5 
(complete ulceration). Fibrotic remodeling was also visualized histologically and quantified at later time points using 
collagen gene expression.
Results: SAP treatment attenuated the profile of radiation-induced oral mucositis by delaying the time of onset, 
reducing the peak value, and enhancing the resolution of injury. The peak mucositis score was reduced by 
approximately 0.5 grade in SAP-treated animals. The number of animal days with a score of ≥ 3 was reduced by 48% in 
the SAP-treated group, compared with the saline control group (P < 0.01). SAP also inhibited the extent of tissue 
remodeling and decreased radiation-induced increases in myofibroblast number. Attenuated collagen deposition and 
gene expression was also observed in the cheek pouches of hamsters treated with SAP at both 16 and 28 days post-
radiation.
Conclusions: SAP treatment significantly attenuated radiation-induced injury. In particular, SAP attenuated the 
severity of OM and inhibited pathogenic remodeling. This suggests that SAP may be a useful therapy for the palliation 
of side effects observed during treatment for head and neck cancer.
Background
Oral mucositis is a common side effect of chemotherapy
and radiotherapy, with mucositis occurring to some
degree in more than one-third of patients receiving anti-
neoplastic drug therapy [1]. Moderate to severe mucositis
occurs in virtually all patients who receive radiation ther-
apy for tumors of the head and neck. It typically begins at
cumulative exposures of 15 Gy and then worsens when
total doses exceed 60 Gy [1-4]. The ensuing injury signifi-
cantly impairs quality of life and can hamper the sched-
u l e d  c o u r s e  o f  t h e r a p y ,  t h u s  r e d u c i n g  e f f i c a c y  o f
treatment. The complex pathoetiology is associated with
the induction of a series of biologic pathways within the
submucosa. Pronounced epithelial cell apoptosis and the
generation of pro-inflammatory cytokines such as tumor
necrosis factor (TNF)-α and interleukin (IL)-1β [5], and
pro-fibrotic mediators such as transforming growth fac-
tor (TGF)-β [5], result in the breakdown of the oral
mucosa, causing formation of ulcerative lesions. In
patients with granulocytopenia, the ulcerations that
accompany mucositis are common portals of entry for
indigenous oral bacteria, often leading to sepsis or bacte-
remia [3]. Fibrotic remodeling of the damaged tissue then
serves to seal off the region; however, if the extent of
remodeling is overexuberant, the surrounding tissue
becomes involved, resulting in a loss of elasticity that pro-
duces detrimental functional consequences. This, along
with pronounced mucositis after directed radiotherapy or
certain chemotherapies, can cause the patients to inter-
rupt their scheduled treatments, thereby affecting long-
term survival [3].
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Serum amyloid P (SAP) is a member of the pentraxin
family of serum proteins and has been previously shown
to reduce fibrosis in experimental models [6-9]. This pro-
tein is highly conserved between species. In vitro, SAP
has been described as inhibiting monocyte to fibrocyte
differentiation and macrophage activation [9,10]. Fibro-
cytes are bone marrow-derived CD45+ collagen I+ cells
that are thought to contribute to excess extracellular
matrix (ECM) deposition at sites of fibrosis. In vivo, SAP
also decreases fibrocyte and macrophage numbers in
models of cardiac and pulmonary fibrosis [6,7]. More
recently, an association of fibrocytes with both the prog-
nosis and severity of interstitial lung disease has been
described [11]. SAP also decreases the expression of mac-
rophage activation markers in models of pulmonary and
renal fibrosis [8,9].
The standard therapy for mucositis is predominantly
palliative, including application of topical analgesics such
as lidocaine and/or systemic administration of narcotics
a n d  a n t i b i o t i c s .  I n  t h i s  s t u d y ,  w e  u s e d  a n  e s t a b l i s h e d
hamster cheek-pouch model of radiation-induced
mucositis to determine if SAP treatment affects either the
clinical or pathological hallmarks of the disease. We fur-
ther assessed the potential effect of SAP on the down-
stream fibrosis mediated by radiation.
Methods
Animals
Male Syrian golden hamsters (CRL) weighing approxi-
mately 80-90 g (5-6 weeks old, n = 12 per group) were
used in this study. All experiments were conducted under
Biomodels Institutional Animal Care and Use Committee
regulations and protocols.
Acute model of radiation-induced mucositis
Animals were given an acute radiation dose of 40 Gy
directed to their left buccal cheek pouch, with the right
cheek pouch serving as the non-irradiated control, as
previously described [12]. Briefly, radiation was gener-
ated with a 160 KV potential (18.75 mA) source at a focal
distance of 210 mm, hardened with a 3.0 mm Al filtration
system (Kimtron Polaris II, Kimtron Inc, Woodbury, CT,
USA). Irradiation targeted the left buccal pouch mucosa
at a rate of 1.32 Gy/minute. Before irradiation, animals
were anesthetized with intraperitoneal (i.p.) ket-
amine:xylazine (160 mg/kg:8 mg/kg). The left buccal
pouch was everted and fixed, and isolated using a lead
shield.
SAP administration
SAP in 10 mM Tris, 140 mM NaCl buffer (EMD Biosci-
e n c e s ,  S a n  D i e g o ,  C A ,  U S A )  w a s  a d m i n i s t e r e d  b y  i . p .
injection at a dose of 2 mg/kg with dosing initiated 1 day
before radiation (day -1) or immediately after radiation
(day 0). Animals were dosed daily on days 0 to 7, every 2
days on days 0 to 12, or every 2 days on days -1 to 26.
Additional groups of animals were dosed every 2 days
with phosphate-buffered saline (PBS) on days 0 to 12 or
days -1 to 26, and served as vehicle control groups. The
dose level of 2 mg/kg SAP was chosen as this approxi-
mately doubles predicted endogenous SAP levels in the
hamster.
Evaluation of oral mucositis
Oral mucositis was evaluated from photographs by two
independent, trained observers who were blinded to the
study groups. The extent of mucositis was scored visually
by comparison with a validated photographic scale (clini-
cal scoring) (0 = completely healthy pouch with no vaso-
dilation or erythema; 1 = light to severe erythema and
vasodilation with no visible erosion of mucosa; 2 = severe
erythema, vasodilation and erosion of the superficial
mucosa; 3 = severe erythema and vasodilation, formation
of off-white ulcers in ≥ 1 places with the cumulative size
of the ulcers equaling approximately one-quarter of the
pouch; 4 = severe erythema and vasodilation, cumulative
size of ulcers encompassing approximately half the
pouch; 5 = virtually all of the pouch is ulcerated, loss of
pliability with the pouch only partially extractable from
the mouth).
Gene expression analysis
For gene analysis, cheek pouch tissue was homogenized
in lysis buffer (Panomics, Freemont, CA, USA), in accor-
dance with the manufacturer's instructions. Owing to the
high levels of collagen present in the hamster cheek
pouch, homogenized samples were passed through a 0.45
μm cellulose nitrate plate (Whatman, Piscataway, NJ,
USA) before mRNA analysis. mRNA levels were quanti-
fied using a branched-DNA technology-based method
(QuantiGene Reagent System; Panomics), according to
the manufacturer's protocols. Transcript levels of fibrosis
and macrophage-related genes were normalized to β-
actin mRNA.
Histology
Cheek pouches fixed in 10% normal buffered formalin
(NBF) were cut into horizontal sections perpendicular to
the long axis of the cheek pouch. Samples were changed
to 70% alcohol, embedded in paraffin and cut into sec-
tions approximately 5 μm thick. Serial sections were
stained with hematoxylin and eosin (H&E) for gross mor-
phology, or Masson's trichrome stain for collagen deposi-
tion. Sections were examined using am inverted
microscope and camera (Micromaster; Fisher Scientific
Pittsburgh, PA, USA).
Histological fibrosis scoring
H&E-stained slides were assessed for fibrosis according
to a six-point scale (0 = no fibrosis noted; 1 = minimalMurray et al. Fibrogenesis & Tissue Repair 2010, 3:11
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fibrosis; 2 = mild fibrosis; 3 = moderate fibrosis; 4 =
marked fibrosis; 5 = severe fibrosis). Analysis was
directed by a board-certified veterinary pathologist
blinded to the study group designation.
Immunohistochemistry
Formalin-fixed, paraffin wax-embedded cheek pouch
sections were analyzed for immunohistochemical local-
ization of α-smooth muscle actin (α-SMA) expression
using an indirect immunoperoxidase procedure. Sections
were dewaxed with xylene, rehydrated in graded concen-
trations of ethanol, and blocked with normal horse
serum. Mouse anti-α-SMA monoclonal antibody (A5228,
clone 1A4; Sigma-Aldrich, Missouri, MO, USA) and con-
trol normal rabbit IgG were diluted in PBS to a final con-
centration of 5 μg/ml. Anti-α-SMA or IgG were added to
histological sections for 60 min, after which each tissue
section was washed thoroughly with PBS. A secondary
biotinylated donkey-anti-mouse IgG (Jackson Immu-
noResearch, West Grove, PA, USA) was added to each
section for 1 hour. Slides were then thoroughly washed
and α-SMA visualized with a commercial staining kit
(HRP-Dab Staining Kit; Vector Laboratories, Burlingame,
CA, USA).
In vitro fibroblast assay
Normal human dermal fibroblasts (NHDF) were plated
into 24-well plates (Costar, Corning, NY, USA) at 100,000
cells/well, and allowed to adhere for 8 hours. The cells
were then washed with PBS and cultured overnight in
serum-free media (Dulbecco's modified Eagle's medium
(DMEM) with L-glutamine, penicillin and streptomycin).
Cells were then stimulated for 24 hrs in the presence or
absence of platelet-derived growth factor (PDGF) anti-
body (200 ng/mL) and/or SAP (1 or 4 μg/mL). Prolifera-
tion was assessed a cell proliferation ELISA with 5-
bromo-2-deoxyuridine incorporation (Roche Applied
Science, Roche Diagnostic Corporation, Indianapolis, IN,
USA).
Epithelial to mesenchymal transition assay
Experiments were performed in A549 cells grown to 60%
confluence in six-well plates (BD Biosciences, Missis-
sauga, ON, USA), which were grown in DMEM contain-
ing 10% fetal bovine serum (FBS) at 37°C in 5% CO2 in air.
Before each experiment, cells were incubated in DMEM
with 0.5% FBS for 24 hours. A549 cells were then incu-
bated with or without TGF-β1 (10 ng/mL) or SAP (1, 5 or
10 μg/mL) or both for 48 hours. After this, cells were
lysed in protein extraction buffer supplemented with
phenylmethanesulfonyl fluoride, phosphatase inhibitor
cocktail 2, and protease inhibitor cocktail (Sigma-
Aldrich). Lysates at a concentration of 50 ng/ml were
then separated by electrophoresis in SDS-PAGE gels and
electrotransferred to nitrocellulose membranes, which
then underwent western blotting analysis with antibodies
directed against extra domain-A (EDA)-fibronectin
(EDA-FN) (MAB1940; Chemicon International, Temec-
ula, CA, USA) and E-cadherin (SC-8426, Santa Cruz Bio-
technology, Santa Cruz, CA, USA). Hsp90 (BD610418,
BD Biosciences, Mississauga, ON, USA) was used as a
protein loading control.
Statistics
For each evaluation day, the scores of the vehicle control
group were compared with those of the treated groups
using non-parametric rank sum analysis. Statistical dif-
ferences between treatment groups were determined
using the Student t-test, Mann-Whitney U  test and χ2
analysis, with a critical value of 0.05 as appropriate. P val-
ues of <0.05, <0.01 or P < 0.005 *referred to as *, ** or ***,
respectively) were considered significant.
Results
Radiation-induced fibrosis
The clinical course of mucositis is well characterized in
this hamster cheek-pouch model of radiation-induced
mucositis [12], with peak mucosal breakdown occurring
between days 14 and 18. The development of ulcerative
mucositis in this study was consistent with historical data
from our laboratory. To assess the extent of downstream
tissue remodeling as it pertains to collagen deposition,
hamsters received a single dose of radiation (40 Gy) spe-
cifically to the left everted cheek pouch on day 0 and were
killed 16 or 28 days later. Cheek pouches were sectioned
and stained with Masson's trichrome to visualize areas of
excess collagen accumulation (Figure 1). In non-irradi-
ated cheek pouches, densitometric analysis showed
approximately 43% trichrome positivity in each of the
cheek pouches analyzed (Figure 1A, B). At day 16 in irra-
diated cheek pouches, there were large areas of ulceration
densely infiltrated with neutrophils, with surrounding
necrosis in the muscle layer (Figure 1D). Irregular regions
of fibrosis were observed beneath the muscular layer of
the buccal pouch (Figure 1C). At day 28, there were fewer
regions of epithelial ulceration, and the extent of inflam-
mation was also reduced, indicating a degree of mucositis
resolution at the histopathological level (Figure 1F). How-
ever, the cheek pouches exhibited more pronounced
fibrosis at day 28 (60% trichrome positivity; Figure 1E),
with the aberrant ECM being better organized compared
with the day 16 time point (58% trichrome positivity; Fig-
ure 1C). This increase in ECM deposition indicates that
the hamster cheek-pouch model is suitable to assess the
anti-fibrotic potential of SAP as it pertains to radiation-
induced fibrosis.
SAP inhibits radiation-induced mucositis
The effect of SAP on radiation-induced mucositis was
initially assessed by administering SAP (2 mg/kg, i.p.) toMurray et al. Fibrogenesis & Tissue Repair 2010, 3:11
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the hamsters every 2 days from days 0-12 after radiation
exposure. In control (PBS-treated) animals, the peak in
m u c o s i t i s  o c c u r r e d  a t  d a y  1 8 ,  w i t h  a  m e a n  ±  S E M
mucositis score of 3.25 ± 0.11 (Figure 2). After the peak at
day 18, the extent of mucositis subsided, with a mean
mucositis score of 0.81 ± 0.10 on day 6. In the SAP-
treated animals, the peak in radiation-induced mucositis
a l s o  o c c u r r e d  a t  d a y  1 8 .  H o w e v e r ,  t h e  m a g n i t u d e  o f
mucositis was lower (2.88 ± 0.09), with significantly
reduced mucositis scores being observed in the SAP-
treated (day 0-12) animals at days 14 and 16 compared
with vehicle controls (P < 0.05). In fact, the SAP-treated
animals never reached a group mean of 3 throughout the
study, whereas vehicle-treated animals reached a group
mean of >3 by day 16. Another significant effect of SAP
was observed at day 26, with SAP-treated animals having
a lower mean mucositis score (0.25 ± 0.11) than vehicle
control hamsters (P < 0.01). Totaling the number of days
that animals had a mucositis score of ≥ 3 (severe mucosi-
tis and of clinical significance), revealed that animals
treated with SAP had a significantly attenuated duration
of severe mucositis (48% relative reduction, P  < 0.01).
Taken together, these results suggest that SAP treatment
delays the onset, reduces the peak dampens the total
extent, and promotes resolution of mucositis.
SAP inhibits radiation-induced fibrosis in the hamster 
cheek pouch
Histological analysis and quantification of H&E-stained
sections of the cheek pouches of hamsters exposed to
radiation, assessing both fibrotic changes and overt
inflammation, indicated that there was a time-dependent
increase in overall pathogenic changes, with scores peak-
ing at day 16 (2.75 ± 0.25) and showing only a moderate
reduction by day 28 (2.25 ± 0.25) (Figure 3). As with vehi-
cle controls, hamsters treated with SAP (day 0-12) had
increased fibrous material at day 16 (2.50 ± 0.29) com-
pared with non-irradiated control cheek pouches and
compared with day 8 hamster cheek pouches. However,
there was significantly reduced fibrous material in the
cheek pouches of animals treated with SAP at day 28
(1.50 ± 0.29) compared with vehicle control-treated ani-
mals (P < 0.05; Figure 4).
Acute dosing with SAP at the time of radiation gives 
greatest protection
To determine the optimum dosing strategy of SAP to
attenuate radiation-induced mucositis and fibrosis, we
assessed the efficacy of various dosing schedules. Ham-
sters were treated with SAP immediately after radiation
(day 0) and given SAP either every 2 days from day 0 to 12
or daily from days 0 to 7. In another group of animals,
SAP treatment was initiated 1 day before radiation and
was given every 2 days until the end of the study (days -1
to 26). Mucositis scoring indicated that all dosing regi-
mens reduced the peak of mucositis and enhanced its res-
olution (Figure 3A), thus attenuating the overall time that
animals actually had severe mucositis (Figure 3B).
Analysis of procollagen III gene expression in the ham-
ster cheek pouches, as a surrogate for the extent of fibro-
sis, determined that hamsters treated with SAP daily
Figure 2 Effect of serum amyloid P (SAP) on radiation-induced 
mucositis. Hamsters were exposed to radiation and treated with SAP 
(2 mg/kg, i.p.) every 2 days from days 0 to 12. Mean mucositis scores 
were determined in phosphate buffered saline (vehicle)-treated (open 
symbols; n = 12) and SAP-treated (filled symbols; n = 12) animals from 
days 6 to 26. *P < 0.05, **P < 0.01 compared with PBS vehicle-treated 
control irradiated hamster cheek pouches.
Figure 1 Representative histopathology of radiation-induced fi-
brosis. Hamsters were exposed to radiation (40 Gy) on day 0. At subse-
quent time points, cheek pouches were removed, sectioned and 
stained with Masson's trichrome to visualize collagen deposition. Rep-
resentative cheek pouch sections are shown for (A,B) non-irradiated 
controls, (C,D) day 16 post-radiation, and (E,F) day 28 post-radiation.
A
C
E
B
D
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from days 0-7 had significantly less procollagen III gene
transcript compared with the PBS vehicle-treated or the
hamsters treated with the other two SAP dosing strate-
gies when measured at day 16 (Figure 5A) or day 28 (Fig-
ure 5B). Quantification of myofibroblast number, as
visualized by immunohistochemical staining of α-SMA
(Figure 6A-H) confirmed the anti-fibrotic activity of SAP
at day 16 in animals dosed on days 0-7 (Figure 7). How-
ever there were also significantly fewer α-SMA positive
cells at both day 16 and day 28 in animals dosed every 2
days from days 0 - 12, and also at day 28 in the animals
dosed with SAP throughout the study (Figure 7).
SAP does not promote fibroblast proliferation or epithelial 
to mesenchymal transition
To determine the potential mechanistic anti-fibrotic
activity of SAP on mesenchymal cells, we initially
assessed the effect(s) of SAP on fibroblast proliferation,
alone or in combination with known proliferative media-
tors. As expected, PDGF promoted significant prolifera-
tion (Figure 8). By contrast, SAP had no direct
proliferative effect, nor did it modulate PDGF-induced
proliferation when added concomitantly (Figure 8A). We
also assessed the effects of SAP on epithelial to mesen-
chymal transition (EMT) using the human lung epithelial
cell line A549. Incubation with TGF-β1 at 10 ng/ml
induced phenotypic changes consistent with EMT (Fig-
ure 8B). Morphologically, the cells lost their rounded cob-
blestone appearance and became stellate. Exposure to
TGF-β1 also induced expression of the mesenchymal
marker EDA-FN, together with downregulation of the
epithelial marker E-cadherin (Figure 8B). Addition of
SAP (1-10 μg/ml) alone had no obvious effect on the phe-
notype of A549 cells or on the expression of E-cadherin
or EDA-FN (Figure 8B). Similarly, when added at the
s a m e  t i m e  a s  T G F β 1 ,  S A P  h a d  n o  e f f e c t  o n  T G F β 1 -
induced changes in cell morphology or on expression of
EDA-FN or E-cadherin (Figure 8B).
Discussion
We have shown that SAP treatment results in a signifi-
cant reduction in the two pathological sequelae of clinical
radiotherapy and chemotherapy, mucositis and fibrosis.
In the oral mucosa, directed radiation therapy induces
apoptosis of the epithelial barrier which initiates an
inflammatory cascade, characterized by nuclear factor
(NF)κB activation [13]. The ensuing fibrotic response
serves to provide adequate local wound healing; however,
this can be overexuberant and limit tissue elasticity and
function. SAP treatment dampened the extent of mucosi-
tis, as demonstrated by a reduction in the time to onset
and attenuation in both the peak and duration of pathol-
ogy. SAP also attenuated the fibrotic wound healing
response.
Figure 3 Attenuation of radiation-induced mucositis with an al-
tered serum amyloid P (SAP) dosing schedule. Hamsters were ex-
posed to radiation and treated with SAP (2 mg/kg, i.p. every 2 days 
from day 0 to 12, daily from days 0 to 7, or every 2 days from days -1 to 
26 (n = 12 per group) or vehicle control (phosphate-buffered saline 
(PBS), i.p. every 2 days from days 0 to 12; n = 12). (A) Mean mucositis 
scores were determined in PBS (vehicle)-treated (open symbols) and 
SAP-treated (filled symbols) animals from days 6 to 28. (B) The total 
number of days that hamsters had a mucositis score of ≥ 3 was calcu-
lated. *P < 0.05, **P < 0.01 compared with PBS vehicle-treated control 
irradiated hamster cheek pouches.
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Figure 4 Reduction in radiation-induced fibrosis mediated by se-
rum amyloid P (SAP). Hamsters were exposed to radiation (40 Gy) on 
day 0. At subsequent time points, cheek pouches were removed, sec-
tioned and stained with haematoxylin and eosin, and extent of fibrosis 
was assessed. Original magnification: left, × 11; right × 200 (region in 
the inset box). Bars represent the mean ± SEM of four animals per 
group.
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In the present study, oral mucositis was scored using
the established WHO criteria [14]. Using this scale, a
score of ≥ 3 [represents severe mucositis that affects a
patient's quality of life, with 70% of patients requiring
feeding tubes to maintain adequate nutrition [14]. Fur-
ther, in approximately 35% of patients with grade 3-4
mucositis, subsequent rounds of radiotherapy may be
delayed or prevented, leading to less successful clinical
therapy. Lower grades of mucositis may also significantly
affect patient quality of life. Grade 1 is associated with
pain that is sufficiently severe to require opioid analgesia.
At grade 2, patients have difficulty or an inability to swal-
low due to ulcerations in the mouth and throat, which, if
severe, may necessitate total parenteral nutrition and
rehydration. Early expression of mitogen-activated pro-
tein kinase (MAPK) is observed within 8 hours post-radi-
ation [15]. MAPK may function with NF-κB as a
coactivator of a large number of genes involved in
mucosal injury [16]. The activation of NF-κB due to radi-
ation results in upregulation of a variety of genes leading
to increased production of pro-inflammatory cytokines
including TNF-α, IL-1β and IL-6 [17]. Targeted radiation
has been shown to increase cyclooxygenase-2 expression
in submucosal tissues, and this parallels the development
of ulcerative mucositis [18]. In this study, we show that
SAP treatment reduced the number of days that animals
had a mucositis score of ≥ 3, indicating that SAP may pro-
vide significant palliative care, allowing the continuation
of radiotherapy. Histopathologic assessment of cheek
pouches indicated a significant reduction in the extent of
leukocyte infiltration after SAP treatment. SAP has
recently been shown to reduce inflammation in several
experimental models of fibrosis through an Fc receptor-
dependent mechanism [7,9,19]. Therefore the anti-
Figure 5 Attenuated fibrosis-associated gene expression after serum amyloid P (SAP) treatment. Hamsters were exposed to radiation and 
treated with SAP (2 mg/kg, i.p. every 2 days from days 0 to 12, daily from days 0 to 7, or every 2 days from days -1 to 26) or vehicle control (phosphate-
buffered saline (PBS), i.p. every 2 days from days 0-12). Procollagen III gene expression was determined in the irradiated cheek pouches using branched 
DNA technology at (A) day 16 and (B) day 28. Bars represent the mean ± SEM. of four animals per group.
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inflammatory effect of SAP treatment on mucositis may
occur via a similar mechanism. Owing to the model limi-
tations, with limited hamster reagents available, we were
confined by the number of endpoints we could assess.
The pathogenesis of mucositis is multifactorial, involv-
ing the interaction of oral mucosal epithelial cells,
endothelial cells, connective tissue and the submucosal
infiltrate [5]. There are four interdependent phases: (1) an
inflammatory/vascular phase, (2) an epithelial phase, (3)
an ulcerative/bacteriological phase, and finally (4) a heal-
ing/resolution phase [20]. Radiation directly damages cel-
lular DNA, which results in cellular apoptosis and also
inhibits homeostatic cell renewal. The debris generated
during apoptosis promotes inflammation via numerous
cascades including Toll-like receptor signaling and NFκB
activation. Non-phlogistic clearance of these pro-inflam-
matory signals by macrophages acts to switch off the
immune response, thus limiting damage to host tissue
[21]. Inadequate clearance by macrophages has been
shown to contribute directly to a number of acute and
chronic diseases [22]. SAP clears apoptotic and necrotic
debris [9,23], which then helps to promote a quiescent
clearance of the damage-associated molecular patterns
(DAMPs), thus minimizing the extent of inflammation.
Further, inhibiting apoptosis has been shown to reduce
oral mucositis [24]. Subsequent studies assessing the
effect(s) of SAP on radiation-induced apoptosis and
necrosis would help to determine if this is part of the pro-
tective therapeutic mechanism.
The ensuing fibrotic response mediated by radiation is
associated with an increase in ECM deposition. Fibro-
blasts, when activated, produce various ECM compo-
nents and can also differentiate into myofibroblasts,
which are more contractile and more readily synthesize
ECM, resulting in a greater loss of tissue elasticity. SAP
decreased the amount of ECM and the number of myofi-
broblasts in the cheek pouch after radiation. SAP did not
directly modulate fibroblast proliferation; therefore this
anti-fibrotic mechanism in vivo is upstream of direct
fibroblast activity.
Another key stromal cell type demonstrated to promote
fibrosis is the epithelial cell. Epithelial cells stimulated
with the prototypic growth factor TGF-β result in a tran-
sition of cell phenotype away from the resident epithelial
cell and towards a motile, ECM-producing mesenchymal
cell. This process is referred to as epithelial to mesenchy-
mal transition (EM)T and is understood to contribute to
lung, liver and kidney fibrosis [25-27]. TGF-β is the pro-
totypic inducer of EMT. However, we determined that
SAP did not modulate TGFβ-induced EMT, nor did SAP
have any direct EMT effects.
Figure 6 Reduction in radiation-induced α-smooth muscle actin 
(α-SMA) expression with serum amyloid P (SAP) treatment. Ham-
sters were exposed to radiation and treated with SAP (2 mg/kg, i.p. ev-
ery 2 days from days 0 to 12, daily from days 0 to 7, or every 2 days from 
days -1 to 26) or vehicle control (phosphate-buffered saline (PBS), i.p. 
every 2 days from days 0 to 12). At either 16 or 28 days post-radiation, 
animals were killed and cheek pouches removed, sectioned and 
stained with anti-α-SMA to visualize myofibroblast accumulation and 
vascular smooth muscle cells. (A-H) Representative histopathology 
from irradiated cheek pouches from the vehicle groups (A) at day 16 
and (B) day 28; from the first SAP group (2 mg/kg every 2 days, days -1 
to 26) at (C) day 16 and (D) day 28; from the second SAP group (2 mg/
kg daily, days 0 to 7) at (E) day 16 and (F) day 28; and from the third SAP 
group (2 mg/kg every 2 days, days 0 to 12) at day 16 (G) and day 28 (H).
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H
Figure 7 The total number of α-smooth muscle actin (α-SMA)-
positive cells was quantified morphometrically. Bars represent 
the mean ± SEM of four animals per group. *P < 0.05 compared with 
PBS (vehicle) control irradiated hamster cheek pouches. Original mag-
nification × 400.
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Recent studies have indicated that during fibrosis, SAP
directs monocyte to profibrotic fibrocyte or M2 mac-
rophage differentiation [8-10]. This suggests that the
reduction in myofibroblast number in the cheek pouch
after SAP treatment is due to a mechanism upstream of
direct modulation of fibroblast activity and may be due to
modula tion of monocyt e differ en tia tion. F ut ure st udies
assessing the monocyte/macrophage phenotype in the
cheek pouch should determine if there is also a profi-
brotic phenotype associated with the pathology observed
in this model, as has been reported clinically [28]. Fur-
ther, determining whether SAP can direct the mac-
rophage phenotype away from a fibrotic M2 phenotype
and towards a classic M1 macrophage phenotype will be
insightful.
The observed utility of SAP as a therapeutic for
mucositis in reducing both the acute inflammation and
the downstream fibrosis is exciting. Various potential
therapeutics have been assessed clinically for oral
mucositis including recombinant IL-11 [29], granulocyte-
macrophage colony-stimulating factor (GM-CSF) [30,31],
G-CSF [32] and TGF-β3 [33]. Currently, the only
approved treatment for mucositis is palifermin (Kepiv-
ance®; Biovitrum, Stockholm, Sweden), which is approved
for the treatment of oral mucositis in patients undergoing
bone marrow ablation for transplant. Palifermin is a
recombinant keratinocyte growth factor and, as with all
the other agents tested clinically, promotes epithelial cell
proliferation, thus providing a denser barrier to protect
the underlying mucosal tissue. By contrast, we have dem-
Figure 8 Serum amyloid P (SAP) has no effect on fibroblast proliferation or transforming growth factor (TGF)-β-mediated epithelial to mes-
enchymal transition (EMT). (A) Normal human dermal fibroblasts (NHDF) were stimulated with platelet-derived growth factor (PDGF; 200 ng/mL) 
for 24 hours in the presence or absence of SAP. Proliferation was quantified using 5-bromo-2-deoxyuridine incorporation. (B) A549 cells were stimu-
lated with TGF-β1 in the presence or absence of SAP for 48 hours. The resultant lysates were assessed for the epithelial marker E-cadherin or the mes-
enchymal marker extra domain-A (EDA)-fibronectin using western blotting analysis. *P < 0.05, **P < 0.01, ***P < 0.005.
A.  
0.0
0.2
0.4
0.6
0.8
1.0
control
1g/ml SAP
4g/ml SAP
media alone 200 ng/ml PDGF
* *** **
O
D
4
5
0
 
B.  
Fibronectin EDA 
E Cadherin 
TGF B (ng/mL) 
SAP (g/mL)    
  
 
10
1
10
5
10
10
10
1 
  
5 
  
10
 Murray et al. Fibrogenesis & Tissue Repair 2010, 3:11
http://www.fibrogenesis.com/content/3/1/11
Page 9 of 10
onstrated that SAP has no direct pro-proliferative
response on resident cells, nor does it directly inhibit epi-
thelial cell transition during fibrosis. Importantly, SAP
has more profound effects on the downstream responses
mediated by radiotherapy, namely reducing the ensuing
inflammation and thus limiting stromal cell activation, as
demonstrated by reduced ECM deposition and α-SMA
expression in vivo.
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